PT  - JOURNAL ARTICLE
AU  - Sang Heui Seo
AU  - Yunyueng Jang
TI  - Cold-adapted live attenuated SARS-CoV-2 vaccine completely protects human ACE2 transgenic mice from SARS-CoV-2 infection
AID  - 10.1101/2020.08.04.235689
DP  - 2020 Jan 01
TA  - bioRxiv
PG  - 2020.08.04.235689
4099  - http://biorxiv.org/content/early/2020/08/04/2020.08.04.235689.short
4100  - http://biorxiv.org/content/early/2020/08/04/2020.08.04.235689.full
AB  - Severe acute respiratory syndrome coronavirus (SARS-CoV-2) has infected more than 16,000,000 people and has caused the death of more than 650,000 individuals since December 2019. A safe and effective vaccine that can provide herd immunity against SARS-CoV-2 is urgently needed to stop the spread of this virus among humans. Many human viral vaccines are live attenuated forms of viruses that elicit humoral and cellular immunity. Here, we describe the development of a cold-adapted live attenuated vaccine (SARS-CoV-2/human/Korea/CNUHV03-CA22°C/2020) by gradually adapting the growth of SARS-CoV-2 from 37°C to 22°C in Vero cells. This vaccine can be potentially administered to humans through nasal spray. Its single dose was observed to strongly induce the neutralising antibody (>640), cellular immunity, and mucosal IgA antibody in intranasally immunised K18-hACE2 mice, which are very susceptible to SARS-CoV-2 and SARS-CoV infection. The one-dose vaccinated mice were completely protected from SARS-CoV-2 infection and did not show loss of body weight, death, and the presence of virus in tissues, such as the nasal turbinates, brain, lungs, and kidneys. Taken together, the cold-adapted live attenuated SARS-CoV-2 vaccine developed by us may contribute to saving of human lives from the threat of SARS-CoV-2.Competing Interest StatementThe authors have declared no competing interest.